Autolus Therapeutics (AUTL) EBIT (2017 - 2025)
Historic EBIT for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$71.6 million.
- Autolus Therapeutics' EBIT fell 551.74% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 2518.31%. This contributed to the annual value of -$241.4 million for FY2024, which is 3434.87% down from last year.
- Per Autolus Therapeutics' latest filing, its EBIT stood at -$71.6 million for Q3 2025, which was down 551.74% from -$61.2 million recorded in Q2 2025.
- In the past 5 years, Autolus Therapeutics' EBIT registered a high of -$40355.0 during Q3 2021, and its lowest value of -$75.9 million during Q4 2024.
- For the 5-year period, Autolus Therapeutics' EBIT averaged around -$44.4 million, with its median value being -$39.9 million (2021).
- Per our database at Business Quant, Autolus Therapeutics' EBIT surged by 9990.55% in 2021 and then plummeted by 9244615.29% in 2022.
- Quarter analysis of 5 years shows Autolus Therapeutics' EBIT stood at -$23.1 million in 2021, then skyrocketed by 49.57% to -$11.6 million in 2022, then crashed by 357.26% to -$53.3 million in 2023, then crashed by 42.41% to -$75.9 million in 2024, then rose by 5.59% to -$71.6 million in 2025.
- Its EBIT stands at -$71.6 million for Q3 2025, versus -$61.2 million for Q2 2025 and -$65.2 million for Q1 2025.